Nearly every year, researchers on drug company payrolls publish some ridiculous study with claims that more people may be dying from suicide due to a black box warning about an increased risk of suicide in young people on the labels of SSRI and SNRI antidepressants as a ruse to increase sales of drugs.
Judging from a new study out this month, with a June 2, 2009 headline on WebMD stating: “Are Antidepressant Warnings Causing Harm?”, apparently this year is no exception even though in the US there were 164.2 million prescriptions dispensed for antidepressants in 2008, compared to 143 million in 2004, according to IMS Health, a healthcare information company.
The study, published in the Archives of General Psychiatry, claims there has been a drastic drop in the diagnosis of depression in adults and kids.
This week, journalist Philip Dawdy reported on the popular website Furious Seasons that Wyeth’s Effexor me-too drug Pristiq, FDA approved in early 2008, had already generated 1,272 adverse event reports in the FDA’s MedWatch system through the end of 2008, and wrote with live links to the reports:
“It’s discouraging that 17 of those reports involve completed suicides through the end of 2008. There are also 48 reports of suicidal ideation through the end of 2008.”
“That’s a lot in such a short period of time, especially considering that this drug isn’t exactly widely used,” Dawdy points out. Read the rest of this entry »
The National Alliance for Mental Illness is the latest member of the psycho-pharmaceutical cartel whose Big Pharma money trail is under investigation by the US Senate Finance Committee, with Iowa’s Republican Senator Chuck Grassley leading the charge. Read the rest of this entry »
Ten years ago this month the violence and suicide caused by SSRI antidepressants gained international recognition in headlines all over the world when it became known that one of the teen shooters at the Columbine massacre, Eric Harris, had taken Zoloft in the past and was on Luvox at the time of the murder-suicide spree. Read the rest of this entry »